Characteristics of 10-year survivors of high-grade serous ovarian carcinoma

被引:79
|
作者
Dao, Fanny [1 ]
Schlappe, Brooke A. [1 ]
Tseng, Jill [1 ]
Lester, Jenny [2 ]
Nick, Alpa M. [3 ]
Lutgendorf, Susan K. [4 ,5 ]
McMeekin, Scott [6 ]
Coleman, Robert L. [3 ]
Moore, Kathleen N. [6 ]
Karlan, Beth Y. [2 ]
Sood, Anil K. [3 ]
Levine, Douglas A. [1 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Surg, Gynecol Serv, 1275 York Ave, New York, NY 10065 USA
[2] Cedars Sinai Med Ctr, Dept Obstet & Gynecol, Samuel Oschin Comprehens Canc Inst, Womens Canc Program, Los Angeles, CA 90048 USA
[3] Univ Texas MD Anderson Canc Ctr, Ctr RNA Interference & Noncoding RNA, Dept Gynecol Oncol, Dept Canc Biol, Dallas, TX USA
[4] Univ Iowa, Holden Comprehens Canc Ctr, Dept Psychol & Brain Sci, Dept Obstet & Gynecol, Iowa City, IA 52242 USA
[5] Univ Iowa, Holden Comprehens Canc Ctr, Dept Urol, Iowa City, IA 52242 USA
[6] Univ Oklahoma, Dept Obstet & Gynecol, Stephenson Oklahoma Canc Ctr, Div Gynecol Oncol, Oklahoma City, OK USA
关键词
Ovarian cancer; Long-term survival; Neoadjuvant chemotherapy; Surgical cytoreduction; Outcome; Survival; PROGNOSTIC-FACTORS; CANCER; MORTALITY; SURGERY; DISEASE;
D O I
10.1016/j.ygyno.2016.03.010
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective. High-grade serous carcinoma (HGSC) generally presents at an advanced stage with poor long-term (LT) survival. Here we describe clinical features found in women surviving HGSC for ten or more years. Methods. A multi-center research consortium was established between five participating academic centers. Patient selection criteria included high-grade serous ovarian, fallopian tube, or peritoneal carcinoma with at least ten years of follow up. Non-serous, borderline tumors and low-grade serous subtypes were excluded. Results. The 203 identified LT ten-year survivors with HGSC were diagnosed at a median age of 57 years (range 37-84 years). The majority of patients had stage IIIC (72.4%) disease at presentation. Of those who underwent primary cytoreductive surgery, optimal cytoreduction was achieved in 143 (85.6%) patients. After a median follow up of 144 months, 88 (46.8%) patients did not develop recurrent disease after initial treatment. Unexpected findings from this survey of LT survivors includes 14% of patients having had suboptimal cytoreduction, 11% of patients having an initial platinum free interval of <12 months, and nearly 53% of patients having recurrent disease, yet still surviving more than ten years after diagnosis. Conclusions. LT survivors of HGSC of the ovary generally have favorable clinical features including optimal surgical cytoreduction and primary platinum sensitive disease. The majority of patients will develop recurrent disease, however many remained disease free for more than 10 years. Future work will compare the clinical features of this unusual cohort of LT survivors with the characteristics of HGSC patients having less favorable outcomes. (C) 2016 The Authors. Published by Elsevier Inc.
引用
收藏
页码:260 / 263
页数:4
相关论文
共 50 条
  • [21] The "Far Left" of the Morphologic Spectrum of Ovarian High-grade Serous Carcinoma: Case Report of a Purely Noninvasive High-grade Serous Carcinoma Mimicking an Ovarian Serous Borderline Tumor
    Katsakhyan, Levon
    Baraban, Ezra G.
    Dumoff, Kimberly L.
    Burger, Robert A.
    Parikh, Rupal
    Cooper, Kumarasen
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 2021, 40 (02) : 175 - 179
  • [22] Molecular Analysis of High-Grade Serous Ovarian Carcinoma Exhibiting Low-Grade Serous Carcinoma and Serous Borderline Tumor
    Kanno, Kosuke
    Nakayama, Kentaro
    Razia, Sultana
    Islam, Sohel Hasibul
    Farzana, Zahan Umme
    Sonia, Shahataj Begum
    Sasamori, Hiroki
    Yamashita, Hitomi
    Ishibashi, Tomoka
    Ishikawa, Masako
    Imamura, Kayo
    Ishikawa, Noriyoshi
    Kyo, Satoru
    CURRENT ISSUES IN MOLECULAR BIOLOGY, 2024, 46 (09) : 9376 - 9385
  • [23] Differences of chemoresistance assay between invasive micropapillary/low-grade serous ovarian carcinoma and high-grade serous ovarian carcinoma
    Santillan, A.
    Kim, Y. W.
    Zahurak, M. L.
    Gardner, G. J.
    Giuntoli, R. L., II
    Shih, I. M.
    Bristow, R. E.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2007, 17 (03) : 601 - 606
  • [24] BRCA gene testing in women with high-grade serous ovarian carcinoma
    Kansu, Bengi
    Gardner, Jennifer
    Price-Tate, Rachel
    Murch, Oliver
    Murray, Alex
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2021, 41 (06) : 962 - 965
  • [25] Genomic Analysis of Low-Grade Serous Ovarian Tumors Associated with High-Grade Serous Carcinoma or Undifferentiated Carcinoma
    Murali, Rajmohan
    Chandramohan, Raghu
    Soslow, Robert
    Cheng, Donavan
    McCluggage, W. Glenn
    LABORATORY INVESTIGATION, 2016, 96 : 298A - 298A
  • [26] Genomic Analysis of Low-Grade Serous Ovarian Tumors Associated with High-Grade Serous Carcinoma or Undifferentiated Carcinoma
    Murali, Rajmohan
    Chandramohan, Raghu
    Soslow, Robert
    Cheng, Donavan
    McCluggage, W. Glenn
    MODERN PATHOLOGY, 2016, 29 : 298A - 298A
  • [27] Prognostic relevance of gene signatures in high-grade serous ovarian carcinoma
    Konecny, Gottfried E.
    Wang, Chen
    Winterhoff, Boris
    Dering, Judy
    Ginther, Charles
    Chen, Hsiao-Wang
    Hamidi, Habib
    Podratz, Karl C.
    Cliby, William
    Dowdy, Sean Christopher
    Haluska, Paul
    Hartmann, Lynn C.
    Kalli, Kimberly
    Goode, Ellen L.
    Slamon, Dennis J.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [28] Cellular plasticity and migratory modalities in high-grade serous ovarian carcinoma
    Bapat, Sharmila A.
    Varankar, Sagar
    CANCER RESEARCH, 2019, 79 (13)
  • [29] Prognostic impact of neuroendocrine differentiation in high-grade serous ovarian carcinoma
    E. T. Taube
    C. Denkert
    K. Pietzner
    M. Dietel
    J. Sehouli
    S. Darb-Esfahani
    Virchows Archiv, 2015, 466 : 333 - 342
  • [30] Molecular Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma
    Arend, Rebecca C.
    Londono, Angelina I.
    Montgomery, Allison M.
    Smith, Haller J.
    Dobbin, Zachary C.
    Katre, Ashwini A.
    Martinez, Alba
    Yang, Eddy S.
    Alvarez, Ronald D.
    Huh, Warner K.
    Bevis, Kerri S.
    Straughn, J. Michael, Jr.
    Estes, Jacob M.
    Novak, Lea
    Crossman, David K.
    Cooper, Sara J.
    Landen, Charles N.
    Leath, Charles A., III
    MOLECULAR CANCER RESEARCH, 2018, 16 (05) : 813 - 824